MEA Diabetes Market Size

Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The diabetes market in the Middle East and Africa is expected to grow at a CAGR of 7.7 % from 2024 to 2032. It is expected to reach a value of $ 11.7 billion by 2032. The main reasons for this growth are the increasing prevalence of diabetes in the region, the rising rate of obesity, sedentary lifestyles and the aging population. Also, the continuous development of diabetes management devices such as continuous blood glucose monitors and insulin delivery devices will lead to improved patient outcomes and market growth. The major players in the diabetes market, such as Novo Nordisk, Sanofi and Abbott, are constantly investing in research and development to improve their product offerings. Also, strategic initiatives such as the establishment of local collaborations and the investment in digital health solutions will boost market growth. The increasing use of mobile health applications to manage and educate diabetes is a trend that reflects the general trend towards more personalized solutions in health care. These factors will continue to shape the diabetes landscape in the Middle East and Africa.

Regional Market Size

Regional Deep Dive

The Middle East and Africa diabetes market is characterized by a high prevalence of diabetes due to urbanization, changes in lifestyle, and rising obesity rates. The region faces unique challenges, such as a lack of a proper health care system in some countries, but also has significant growth potential, thanks to rising awareness and government initiatives to fight diabetes. The market is also influenced by a variety of factors, such as cultural attitudes towards health, access to care, and the presence of both multinational and local companies striving to offer products and services that meet the needs of the region.

Middle East And Africa

• The World Health Organization (WHO) has launched initiatives in several African countries to improve diabetes care and prevention, focusing on education and awareness programs that aim to reduce the burden of the disease.
• However, the market for diabetes in the Middle East and Africa is expected to grow at a CAGR of 11% over the forecast period. Leading diabetes companies in the region, such as Lifescan and Novo Nordisk, are investing in diabetes management solutions that are adapted to the local market, such as diabetes management applications and affordable insulin delivery systems, which are expected to enhance patient adherence and improve clinical outcomes.
• Cultural factors, such as dietary habits and traditional health practices, significantly influence diabetes management in the region, prompting healthcare providers to adapt their strategies to incorporate local customs and preferences.

Did You Know?

“In the Middle East and North Africa, the prevalence of diabetes is projected to rise to 12.2% by 2045, highlighting the urgent need for effective management and prevention strategies.” — International Diabetes Federation

Segmental Market Size

The Middle East and Africa diabetes market is undergoing significant growth, driven primarily by the growing prevalence of diabetes and rising awareness of the importance of diabetes management. The growing population of diabetic patients, influenced by lifestyle changes and urbanization, is a major factor driving the market. Also, supportive government policies to improve access to health care are driving the market. Furthermore, technological advancements in diabetes management, such as continuous glucose monitoring systems and insulin delivery devices, are expected to enhance patient care and adherence. This has led to a growing trend towards the adoption of diabetes management solutions in the region, with Roche and Abbott leading the way. The main applications are remote patient monitoring and telehealth, which have been well received in urban areas. Lastly, the pandemic of influenza A (H1N1) and the COVID19 virus have increased the demand for telehealth and pushed governments to invest in telehealth. Artificial intelligence in diabetes management tools is shaping the future of the market, as it will allow for more individualized treatment and improved patient outcomes.

Future Outlook

The market for diabetes in the Middle East and Africa is expected to grow at a robust CAGR of 6.08% from 2024 to 2032. The major factor contributing to this growth is the rising prevalence of diabetes in the region, largely a result of changing lifestyles, urbanization and the aging population. In some countries, the prevalence of diabetes is expected to reach 12% by 2032. This will lead to an increased demand for diabetes management solutions, including drugs, monitoring devices and education programs for patients and health care professionals. In addition, technological advancements and government initiatives will have a significant impact on the market. Telemedicine and mobile health applications will enhance patient engagement and help improve diabetes management. Government initiatives to improve access to and affordability of health care, as well as increased investment in the health care system, will also support market growth. In addition, emerging trends such as the development of new drugs and drug delivery systems will play an important role in meeting the diverse needs of diabetics in the region. The market is expected to continue to grow as the diabetes industry in the Middle East and Africa adapts to these changes and becomes more responsive and dynamic.